ArticleFrontiers in neurology
Clinical efficacy and prognostic evaluation of endovascular treatment in acute basilar artery occlusion.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy and prognosis of endovascular treatment (EVT) versus best medical management (BMM) in acute basilar artery occlusion (aBAO). Methods: We retrospectively analyzed 120 aBAO patients treated at the Affiliated Zhangjiagang Hospital of Soochow University (Jan 2021-Dec 2024), with 60 patients in each group. Baseline characteristics were comparable. Functional recovery was assessed by mRS and EQ-5D at days 0, 30, and 90. Safety outcomes included symptomatic intracranial hemorrhage, 90-day mortality, and functional deterioration. Neurological function and imaging were evaluated using NIHSS and PC-ASPECTS. Results: EVT showed significantly better mRS at 30 and 90 days (3.0 ± 1.3, 2.5 ± 1.2 vs. 3.8 ± 1.4, 3.3 ± 1.5; Conclusion: EVT significantly improves functional recovery and neurological outcomes in aBAO and demonstrates higher recanalization rates, with comparable safety to BMM, supporting EVT as the preferred treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.